In re BioMarin Pharmaceutical Inc. Securities Litigation
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA
IN RE BIOMARIN PHARMACEUTICAL Case No. 3:20-cv-06719-WHO
INC. SECURITIES LITIGATION
ORDER REGARDING DISCOVERY
DISPUTES Re: Dkt. Nos. 124, 126, 127
12 The parties filed a joint case management statement outlining several disputes. (“Joint 13 Statement”) [Dkt. No. 124]. The parties also filed a joint discovery letter brief (“Joint Letter”) 14 [Dkt. No. 126] and a motion to file that letter under seal1 [Dkt. No. 127]. Most of the parties’ 15 disputes were addressed at the hearing and in the subsequent Minute Order. [Dkt. No. 129]. This 16 Order addresses the remaining disputes. 17 First, plaintiffs confirmed at the hearing that they are able to address the questions that the 18 defendant outlined on page 2 of the Joint Letter, concerning the ranking and rebalancing of the 19 plaintiffs’ stocks during the relevant trading periods. Joint Letter 2:1-8; see also Joint Statement 20 9:16-10:2; 20:22-21:10. Plaintiffs are ORDERED to now answer those questions (in a declaration…